TRR179 Podcast Por TRR179 arte de portada

TRR179

TRR179

De: TRR179
Escúchala gratis

TRR179 goes Podcastby TRR179 Ciencia Enfermedades Físicas Higiene y Vida Saludable Historia Natural Naturaleza y Ecología
Episodios
  • Hepcludex 2.0
    Apr 24 2025

    After about 5 years of Hepcludex it´s time to give a follow up on the experiences with the drug. In this episode we talk to the inventor of bulvertide, S. Urban (project leader in our TRR179) and a clinician expert (P. Lampertico from Milan).

    We will refer to the following questions:

    Which patients benefit from bulevirtide? What about HCC and decomp. cirrhosis?

    Do we need interferon for best efficacy? Are the supply chains of interferon a problem?

    What do we do with treatment failures? When is someone a treatment failure?

    What else is there beyond bulevirtide?

    What are the prospects for bulevirtide/entry inhibition in HBV monoinfection?

    Más Menos
    25 m
  • TRR179 about "Attenuated effector T cells and chronic HBV infection"
    Dec 16 2024

    The authors are refering about the latest paper "Heim, K., Sagar, Sogukpinar, Ö. Sian Llewellyn-Lacey, David A. Price, Florian Emmerich, Anke R. M. Kraft, Markus Cornberg, Sophie Kielbassa, Percy Knolle, Dirk Wohlleber, Bertram Bengsch, Tobias Boettler, Christoph Neumann-Haefelin, Robert Thimme, Maike Hofmann. Attenuated effector T cells are linked to control of chronic HBV infection. Nat Immunol 25, 1650–1662 (2024). https://doi.org/10.1038/s41590-024-01928-4"

    Más Menos
    10 m
  • TRR179 and technologies
    Jul 24 2024

    In todays episode we learn about one of our central and service projects, which serves all research projects with their service on experimental and computational single-cell analysis with high spatial resolution.

    Más Menos
    21 m
Todavía no hay opiniones